Cargando…

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer

Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC). S-1 is often used as a second-line therapy in clinical practice, based on the results of some clinical studies investigating its efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Hiroto, Todaka, Akiko, Yamazaki, Kentaro, Fushiki, Kunihiro, Shirasu, Hiromichi, Kawakami, Takeshi, Tsushima, Takahiro, Hamauchi, Satoshi, Yokota, Tomoya, Machida, Nozomu, Fukutomi, Akira, Onozawa, Yusuke, Andoh, Akira, Yasui, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426227/ https://www.ncbi.nlm.nih.gov/pubmed/33835357 http://dx.doi.org/10.1007/s10637-021-01098-2

Ejemplares similares

Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study
por: Kawakami, Takeshi, et al.
Publicado: (2018)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
por: Kawakami, Takeshi, et al.
Publicado: (2023)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study
por: Kawai, Sadayuki, et al.
Publicado: (2017)

Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
por: Shirasu, Hiromichi, et al.
Publicado: (2020)

Nutrition Support for Head and Neck Squamous Cell Carcinoma Patients Treated with Chemoradiotherapy: How Often and How Long?
por: Ishiki, Hiroto, et al.
Publicado: (2012)

Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients
por: Yasui, Hirofumi, et al.
Publicado: (2019)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer
por: Nishimura, Ari, et al.
Publicado: (2022)

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
por: Kato, K., et al.
Publicado: (2021)

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
por: Kawakami, Takeshi, et al.
Publicado: (2022)

Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
por: Shirasu, Hiromichi, et al.
Publicado: (2018)

Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma
por: Sugiura, Teiichi, et al.
Publicado: (2020)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
por: Okusaka, T, et al.
Publicado: (2010)

Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113
por: Ueno, Makoto, et al.
Publicado: (2021)

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction
por: Shibata, Takashi, et al.
Publicado: (2016)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer
por: Mayanagi, Shuhei, et al.
Publicado: (2017)

Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: a case report
por: Miura, Yuya, et al.
Publicado: (2022)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Utility and safety of a new uneven double-lumen sphincterotome in cases of difficult biliary cannulation
por: Shintani, Shuhei, et al.
Publicado: (2021)

Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2019)

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012)

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone
por: Murata, Akihiro, et al.
Publicado: (2013)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
por: André, T, et al.
Publicado: (2008)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Threaded biliary inside stents are a safe and effective therapeutic option in cases of malignant hilar obstruction
por: Inatomi, Osamu, et al.
Publicado: (2013)

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma
por: Satake, Hironaga, et al.
Publicado: (2016)

Unusual Case of Vogt-Koyanagi-Harada Disease Associated with SAPHO Syndrome: A Case Report
por: Hasegawa, Miyuki, et al.
Publicado: (2018)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Postoperative intestinal obstruction in patients with biliary atresia impedes biliary excretion and results in subsequent liver transplantation
por: Takimoto, Aitaro, et al.
Publicado: (2021)

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
por: Ueno, Makoto, et al.
Publicado: (2021)

Oculo-dento-digital Dysplasia Presenting as Spastic Paraparesis Which Was Successfully Treated by Intrathecal Baclofen Therapy
por: Shinya, Akiko, et al.
Publicado: (2021)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma
por: Xiao, Jing-Bo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2if3fhd717st03n3l98e0mvasi